Compare Adecoagro SA (AGRO) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adecoagro SA vs Bristol-Myers Squibb Co — how do they compare? Adecoagro SA trades at $9.29 (market cap $1.36B), while Bristol-Myers Squibb Co trades at $63.75 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 95.5× Adecoagro SA's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| AGRO | BMY | |
|---|---|---|
Market Cap | $1.36B | $129.94B |
Sector | Technology | Health |
52-Week High | $15.25 | $65.89 |
52-Week Low | $7.13 | $42.60 |
Enterprise Value | $3.39B | $163.92B |
Dividend Yield | 3.15% | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGRO trades at $9.34, down 3.31% today, with a bearish technical signal from moving averages. The company reported mixed earnings, beating in Q3 2025 but missing in the last three quarters. Recent news highlights record adjusted EBITDA in Q2 2026 and an acquisition to expand operations. Valuation ratios like P/S of 0.71 and P/B of 0.77 suggest potential undervaluation, but low net income margins and negative recent EPS pose challenges.
The outlook is cautious; analyst consensus is mixed with 37.5% buy ratings. Upside potential exists from operational expansions and cost management, but risks include earnings volatility, high leverage from acquisitions, and commodity price exposure. Investors should weigh the low valuation against inconsistent profitability and macroeconomic headwinds.
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adecoagro SA
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
